Joanne Xiu: The complexity of biomarkers associated with Anti-PD-1/L1 Therapy Outcomes
Joanne Xiu, Vice President, Clinical and Translational Research at Caris Life Sciences, posted on LinkedIn about recent paper by her as co-author, titled “Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation” soon to be published at Cancer Cell.
Authors: David Hsiehchen, Andrew Elliott, Joanne Xiu, Andreas Seeber, Wafik El-Deiry, Emmanuel S. Antonarakis, Stephanie L. Graff, Michael J. Hall, Hossein Borghaei, Dave S.B. Hoon, Stephen V. Liu, Patrick C. Ma, Rana R. McKay, Trisha Wise-Draper, John Marshall, George W. Sledge, David Spetzler, Hao Zhu.
“I am excited to share a letter soon to be published in Cancer Cell by Cell Press , highlighting the complexity of biomarkers associated with Anti-PD-1/L1 Therapy Outcomes!! The study underscores the power of our multi-omic real-world database to tackle important clinical questions. This is a true testament to the dedication of our POA investigators of Caris Life Sciences. Congratulations to Dr. David Hsieh for his exceptional insight and incredible hard work! Congratulations and thanks to all coauthors.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023